Low-dose Maximal-intent Versus Controlled-tempo Resistance Training on Quality-of-life in Older Adults

May 20, 2025 updated by: Northumbria University

Comparison of Two Low-dose Resistance Training Modalities on Strength, Functional Capacity, and Quality-of-life in Healthy, Community-dwelling, Untrained Older Adults: a Randomised Controlled Trial

The aims of this study were to:

  1. Compare the effects of low-dose Maximal Intent and Controlled Tempo Resistance Training on untrained healthy older adults' quality-of-life, functional capacity, and strength.
  2. Qualitatively explore perceptions of Maximal Intent and Controlled Tempo Resistance Training in older adults.

Older adults are defined as being 60 or more years of age.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
38

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
    • Tyne and Wear
      • Newcastle, Tyne and Wear, United Kingdom, NE1 8ST
        • Northumbria University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Participants were eligible if they were between 30-60 years old
  • Uninjured
  • Had no cardiovascular or neuromuscular conditions
  • Had not participated in lower-limb resistance training in the previous six months.

Exclusion Criteria:

  • Participants were excluded if they had either taken part in any lower-limb resistance training in the last six months
  • Had underlying health condition(s) that prevented them from participating in resistance training
  • Regularly met or exceeded the UK recommended physical activity guideline of 150-minutes of moderate to intense physical activity per week.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Maximal-intent Resistance Training - 3x5 (MI3x5)
The max-intent group were instructed and encouraged to deliberately commit to exerting maximal effort and force during the concentric phase of the leg press with the intention of achieving the greatest velocity possible. This group completed 3 sets of 5 repetitions at 60% one-repetition maximum.
Other: Leg Press Resistance Training (3x5)
Leg Press resistance training at 60% one-rep-max for three sets of five repetitions
Experimental: Maximal-intent Resistance Training - 5x5 (MI5x5)
The max-intent group were instructed and encouraged to deliberately commit to exerting maximal effort and force during the concentric phase of the leg press with the intention of achieving the greatest velocity possible. This group completed 5 sets of 5 repetitions at 60% one-repetition maximum.
Other: Leg Press Resistance Training (5x5)
Leg Press resistance training at 60% one-rep-max for five sets of five repetitions
Experimental: Controlled-tempo Resistance Training - 3x5 (CT3x5)
The controlled-tempo group followed a metronome for both eccentric and concentric phases of the leg press with the intention of maintaining a steady three-second concentric and three-second eccentric. This group completed 3 sets of 5 repetitions at 60% one-repetition maximum.
Other: Leg Press Resistance Training (3x5)
Leg Press resistance training at 60% one-rep-max for three sets of five repetitions
Experimental: Controlled-tempo Resistance Training - 5x5 (CT5x5)
The controlled-tempo group followed a metronome for both eccentric and concentric phases of the leg press with the intention of maintaining a steady three-second concentric and three-second eccentric. This group completed 5 sets of 5 repetitions at 60% one-repetition maximum.
Other: Leg Press Resistance Training (5x5)
Leg Press resistance training at 60% one-rep-max for five sets of five repetitions

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Quality-of-life
Time Frame: At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.
Participant quality of life (measured through focus group questions & SF-36)
At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Balance
Time Frame: At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.
Using the biodex to do a 3 x 20s double-foot eyes-open balance test on Level 6.
At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.
6-minute Walk Test
Time Frame: At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.
A "brisk"-paced 6-minute walk test.
At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.
Timed-up-and-go
Time Frame: At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.
Standing from a chair, walking to a point 3 metres away, turn, and return to the chair as quick as possible whilst walking.
At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.
30-second sit-to-stand (30s-Sit-to-Stand)
Time Frame: At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.
Maximal amount of repetitions a participant can stand up from a chair in 30-seconds.
At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.
Strength
Time Frame: At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.
Participants one-repetition max on leg press machine.
At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.
Body Mass Index
Time Frame: At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.
Mass and height will be combined to report BMI in kg/m^2
At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.
Strength-to-mass Ratio
Time Frame: At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.
Mass and Leg Press 1RM will be combined to calculate strength-to-mass ratio.
At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.
Leg press one-rep-max velocity pre-to-post
Time Frame: At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.
Velocity (m/s) of leg press measured at post-intervention, using baseline one-rep-max.
At baseline and Week 1, mid (Week 4), and post (Week 9), out of a total study duration of 9 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Northumbria University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 30, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 5, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 5, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 29, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 6, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 9, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 23, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 20, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NU2863

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings